-26.7%
CEG vs MRNA
+715.3%
-741.9%
-37.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | +1.3% | -5.4% | -4.1% |
| 7D | -10.6% | -13.8% | +3.2% | -10.3% |
| 30D | -2.5% | -17.7% | +15.2% | -2.1% |
| 3M | -7.9% | +14.3% | -22.2% | -8.4% |
| 6M | -3.0% | +336.0% | -339.0% | -7.9% |
| YTD | -28.2% | +575.9% | -604.2% | -31.3% |
| All | -26.7% | +715.3% | -741.9% | -27.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling